IPO

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

AGT Food and Ingredients' Q2 results signal a successful shift to higher-margin foods, with its packaged foods segment surging despite global headwinds.

Braveheart Bio's stunning IPO debut raised nearly half a billion dollars. We dig into the story behind the numbers and what it signals for the 2026 economy.

The new blank check company debuts with a $100M war chest. A deep dive into its leadership, complex structure, and what its launch means for investors.

iSpecimen's new $5M offering aims to fix its balance sheet and fund expansion. But in a tough market, is this a strategic reset or a temporary patch?

With a fresh $100M, Red Violet isn't just raising capital; it's signaling a major push for acquisitions and innovation in the identity intelligence space.

RECONOVA's massively oversubscribed IPO met a cool reception on its first day, signaling a new era where AI firms must prove profitability, not just potential.

Fresh off its IPO, National Healthcare Properties reports soaring senior housing profits, a dramatic balance sheet overhaul, and a $400M acquisition spree.

Celestica is raising $3 billion to fuel the AI revolution. Is this a masterstroke in building the digital future or a high-stakes gamble for investors?

HMH Holding Inc.'s Q2 results reveal a calculated strategy: using its IPO to fortify its balance sheet while betting on digital tech to outmaneuver market headwinds.

A new $105M SPAC enters the fray. We examine its veteran leadership, its cross-sector strategy, and what it takes to win in today's SPAC market.

Fueled by SpaceX's blockbuster IPO and a stake in a new Jeff Bezos venture, Stack Capital’s Q2 gain offers a rare, liquid window into private tech.

Attovia Therapeutics’ successful IPO injects massive capital into its ambitious pipeline, but can its novel multi-specific antibody platform outmaneuver giants?

Amid a biotech funding revival, Twist's upsized $300M deal signals a bold move to expand its synthetic biology platform, fueling a high-stakes investor debate.

Newly-listed GoldInxs is wasting no time, using its $1.54M IPO to fund an advanced 3D survey on a BC property with 'Blackwater-style' potential.

With promising copper data from its Vent Property, Northern Discovery Metals' phased strategy signals a mature approach to junior exploration.

Strong Q2 results, pivotal deals with AstraZeneca and MSK, and a clear path to profitability signal SOPHiA GENETICS is converting its AI platform into market leadership.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

Cohen & Company's Q2 results showcase its mastery of the resurgent SPAC market. With revenue soaring to $69.5M and major deals inked, the boutique firm proves that specialized expertise can deliver outsized returns.